Ventricular assist device beneficial in youth heart failure

Ventricular assist device beneficial in youth heart failure
For children with severe heart failure, use of a ventricular assist device as a bridge to heart transplantation is associated with improved survival compared with extracorporeal membrane oxygenation, according to a study published in the Aug. 9 issue of the New England Journal of Medicine.

(HealthDay) -- For children with severe heart failure, use of a ventricular assist device as a bridge to heart transplantation is associated with improved survival compared with extracorporeal membrane oxygenation (ECMO), according to a study published in the Aug. 9 issue of the New England Journal of Medicine.

Charles D. Fraser Jr., M.D., from Texas Children's Hospital in Houston, and colleagues conducted a prospective, single-group trial of a ventricular assist device designed as a bridge to heart transplantation for children. Forty-eight children, aged 16 years or younger, were divided into two cohorts of 24 according to body-surface area. Survival was compared with two propensity-score-matched historical control groups who underwent ECMO.

The researchers found that, for in cohort 1 (body-surface area <0.7 m²), at 174 days the median survival time had not been reached, while the median survival time was 13 days in the matched ECMO group. In cohort 2 (body-surface area 0.7 to <1.5 m²) the median survival was 144 days, compared with 10 days in the matched ECMO cohort. Adverse events included major bleeding (42 percent in cohort 1 and 50 percent in cohort 2), infection (63 and 50 percent, respectively), and stroke (29 percent in both cohorts).

"In conclusion, we found that a available in several sizes for use in children as a bridge to was associated with a significantly higher rate of survival, as compared with ECMO," the authors write. "Serious adverse events, including infection, stroke, and bleeding, occurred in a majority of the study participants."

The study was funded in part by Berlin Heart Inc.; several authors disclosed financial ties to pharmaceutical companies and/or Berlin Heart.

More information: Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

US approves first heart pump for children

Dec 18, 2011

The US Food and Drug Administration has approved a first mechanical cardiac assist device for children that can help keep patients alive as they await a transplant.

Recommended for you

Cerebrovascular reserve-based strategy is cost-effective

Jan 29, 2015

(HealthDay)—A decision rule based on assessment of cerebrovascular reserve (CVR) seems to be cost-effective for prevention of stroke in asymptomatic patients with carotid artery stenosis, according to a ...

New hypertension guidelines could save lives and money

Jan 28, 2015

Full implementation of new hypertension guidelines could prevent 56,000 cardiovascular disease events (mostly heart attacks and strokes) and 13,000 deaths each year, without increasing overall health care costs, an analysis ...

Manchester United's rising stars revolutionize heart health

Jan 28, 2015

A unique research project to identify the effects of exercise on young hearts has been announced today [Wednesday 28 January 2015]. Manchester United's Academy players are being put through their paces having their hearts ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.